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A B S T R A C T
Background: Platelet concentrates (PCs) treated by the pathogen inactivation technology (PI) using amotosalen
and UVA illumination (PI-PCs) can be manufactured in additive solutions (PAS-III and PAS-IIIM) or in 100%
Plasma. Quality control (QC) is an integral part of the production. We capitalized on our ongoing QC program to
capture 8 years-worth of data on parameters related to the quality of 116,214 PI-PCs produced under different
manufacturing methods.
Materials and methods: Selected in vitro parameters of metabolism, activation, and storage were analyzed for the
different manufacturing periods to compare PI-PCs versus conventional PCs (C-PCs) resuspended in different
PAS.
Results and discussion: All BC-PCs met quality standards for pH and dose and residual leucocytes. As expected,
storage time correlated with increased lactate, LDH, Annexin V, CD62, sCD40 L levels and decreased glucose and
pH. With PAS-IIIM, higher levels of glucose were observed toward the end of shelf life (p < 0.0001) with lower
platelet activation markers Annexin V (p=0.038) and CD62 (p= 0.0006). Following PI implementation, a low
expire rate of< 0.5% was observed. While a 2.3% mean increase in the production of PCs occurred from 2011 to
2015, the distribution of red blood cell concentrates dropped by 4.4%. A mean incidence of 0.14% for trans-
fusion-related adverse reaction was observed while PI-PCs were distributed, similar to the one observed with C-
PCs. Overall, PI-PCs prepared in additive solutions consistently met quality standards. Those prepared in PAS-
IIIM appeared to have better retention of in vitro characteristics compared to PAS-III though all demonstrated
functionality and clinical effectiveness.
1. Introduction
An important goal in transfusion medicine is to ensure an adequate
supply of high quality platelets. Over the past decades, the introduction
of pre-storage leukodepletion and the use of additive solutions (AS)
contributed toward that goal. The replacement of plasma by AS for the
resuspension of platelets reduces the risk of transfusion complications
due to potential allergic reactions to proteins present in the donor
plasma [1], and it can be modified to further improve platelet storage
conditions while generating savings allowing for plasma to be used for
other applications [2–5].
In recent decades, storage solutions have been developed to im-
prove platelet function by reducing platelet metabolism, lactate pro-
duction and glucose consumption [4,6–10]. Indeed glucose exhaustion
is associated with platelet apoptosis [11]. Acetate can serve as an
alternate energy substrate and its presence in AS decreases glucose
consumption. In addition, acetate consumption results in the produc-
tion of bicarbonate, which helps maintaining pH throughout storage
[2]. The addition of magnesium and potassium in PAS-IIIM may further
decrease platelet activation [4,12,13].
More recently, to reduce the risks associated with PC transfusion,
bacterial testing, sample diversion, point of release testing, and pa-
thogen inactivation technologies were implemented [14,15]. PI tech-
nologies were developed to reduce the risk of transfusion-transmitted
infections associated with PC components. Storage of PCs at ambient
temperature makes them more susceptible to bacterial growth, espe-
cially over prolonged period of storage. PCs treated with the INTERC-
EPT Blood System® for platelets (Cerus Corporation, Concord, CA, USA)
can be stored for up to 7 days without incurring the added risk of
bacterial contamination even in the absence of bacterial screening.
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Prolonged PC storage allows for better inventory management and
distribution logistics resulting in reduced wastage. Furthermore, be-
cause of the robust inactivation of T-cells, INTERCEPT treatment can be
used in lieu of gamma irradiation. This greatly reduces the risk of de-
livering the wrong product to patients with higher risk to develop TA-
GVHD as all products in the inventory are safe for at risk recipients such
as immune-suppressed patients [16,17].
Our center manufactured C-PCs until 2008. In 2008, the INTERC-
EPT Blood System was implemented to treat PCs. The use of PI started
in April 2008 for the treatment of Apheresis-PCs, while the treatment of
BC-CPs was initiated in September of the same year. Until 2012, PI-PCs
were produced in PAS-III (InterSol™, Fenwal) but based on our previous
experience [18,19] and several studies supporting the positive effect of
PAS-IIIM on platelet functionality [8,20], starting in 2012, PI-PCs have
been produced in PAS-IIIM (Table 1).
Our blood center supplies blood components for 31 hospitals that
serve a community of 2.7 million inhabitants; Approximately 15,000
PCs per year are distributed and those evolved over time from being
57% apheresis and 44% pooled buffy-coats (BC-PCs, derived from 5
buffy-coats) in 2009 to being 37% apheresis and 63% BC-PCs in 2015.
PCs quality is assessed on a monthly basis as per the national standards
guidelines21 and the Council of Europe recommendations [22]. This
ongoing quality control (QC) program allowed the capture of data on
platelet quality and function over a span of eight years corresponding to
three time-periods when PI-PCs were manufactured in either PAS-III in
2008, or PAS-IIIM in 2012 and 2015 (Fig. 1) [23]. This study compares
PI-PCs manufactured in either PAS-III or PAS-IIIM to C-PCs
manufactured in PAS-IIIM.
2. Materials and methods
2.1. BC-PC pool preparation
Whole blood (WB) units (450 ± 45mL) were collected from vo-
lunteer donors into quadruple top-and-bottom bags with in-line red
blood cell (RBC) filters (MacoPharma Leucoflex LCR). Following do-
nation, the WB units were placed on butanediol plates and processed
within the next 14–18 h. Processing included a first centrifugation
phase (4497xg, 18min at 22 °C) followed by component separation
using a CompoMat G5 automated blood component separator
(Fresenius) to separate plasma from RBCs while the buffy coat (BC) was
left in the main bag. Individual BCs were allowed to rest for a minimum
of 2 h before pools were prepared; five BCs were pooled(BC-PCs) in PAS
(mean volume 53.8 mL with 38.7% hematocrit). BC-PCs were then
centrifuged, separated and filtered using the automatic OrbiSac system
(TerumoBCT, Lakewood, Co). The final PAS/plasma ratio was ap-
proximately 65/35. The final BC-PC product was allowed to rest for 2 h
after pooling. All pools were visually inspected before proceeding with
amotosalen/UVA treatment.
Air bubbles were systematically removed from all BC-PCs to avoid
negative effects on platelet integrity [24] and the BC-PCs were stored in
polyolefin bags (PL-2410, 1.3 L) under standard conditions at 22 °C
with continuous agitation (Helmer PC 3200 Incubator).
2.2. Pathogen inactivation treatment
Platelets are transferred to the amotosalen container after sterile
connection of the platelet bag to the processing kit. Platelets and
amotosalen solution then flow by gravity into the illumination con-
tainer. The original platelet bag and amotosalen container are subse-
quently removed from the kit. The platelets and amotosalen in the il-
lumination container are mixed end-over-end to ensure thorough
homogenization, placed into the illumination device and illuminated
(3.0 J/cm2 UVA). The treated platelets are then transferred into the
Compound Adsorption Device (CAD) container. After the illumination
container is removed, the treated PCs in the CAD container are kept on
a flatbed agitator for 6–16 hours.
Table 1




NaCl (mM) 77 69
KCl (mM) – 5
MgCl2 (mM) – 1.5
Na3-citrate (mM) 11 10
NaH2PO4/ Na2HPO4 (mM) 28 26
Na-acetate (mM) 33 30
a As per FDA approved package insert [38].
Fig. 1. Assessment of platelet quality and function parameters across 3 time-periods. Data were captured over eight years following the implementation of INTE-
RCEPT Blood System for platelets manufactured in PAS-III in 2008, or in PAS-IIIM in 2012 and 2015. Independently, control data were collected in 2010 on C-PCs
resuspended in PAS-IIIM.
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Subsequently, platelets are transferred by gravity into the storage
container. After the CAD container is removed, the storage container is
placed on a platelet agitator.
For QC data collection, platelets are sampled after mixing of the
storage container by gentle agitation followed by expression into the
sampling pouch, which is sealed, removed and transferred to the ap-
propriate laboratory.
2.3. Data capture
The usual QC parameters were assessed in PC at 14–18 h after in-
activation (volume registration, cell count, swirling visualization and
residual leukocytes count). At the end of the component's shelf life (7
days), pH was determined and samples for bacterial culture taken al-
lowing for inoculation of an anaerobic and an aerobic bottle with 10mL
samples for incubation in the BacT/Alert System (Biomerieux) for 7
days. The number of units tested monthly for cell count was 16% of the
total component production (as per internal quality indicator ≥15%),
and volume registration and visual inspection were carried out in 100%
of the PCs. The other parameters were assessed for∼1.7% of PCs (or 12
per months to satisfy the quality control standards recommending to
test≥1% of the production) [21]. Randomization was organized based
on the number of platelet component produced on a monthly basis and
to insure that approximately 16% were analyzed, 6–7 units were se-
lected daily with representation across blood groups and manufacturing
time. Volume was recorded for all units and the swirling was checked
for all PCs, Approximately 12 units a month or 3 units a week were
randomly selected among units that were not distributed by day 6.
Three storage studies were carried out during the eight years the
INTERCEPT® Blood System for platelets was in use. Those were con-
ducted in 2008 on PAS-III PI-PCs (n=12), and in 2012 (n=12) and
2015 (n= 12) on PAS-IIIM PI-PCs. Data were collected on days 2, 5, 7,
and 9 of storage for 12 PI-PCs. The fractionation method, the device to
obtain the PC-pool, the type of platelet filter (LRP6, Pall) and the
plasma/PAS ratio did not change between these periods. In 2010, data
were collected on C-PCs manufactured in PAS-IIIM (n=13). The
number of PCs distributed and the adverse events (AEs) of transfusion
of this component were monitored through passive reporting.
2.4. In vitro parameters
The platelet content and mean platelet volume (MPV) were mea-
sured using the XT-2000i Sysmex autoanalyzer. The pH was measured
at 22 °C using a pH meter (Crysson MicropH2001). Swirling was as-
sessed visually and given a numerical value of 0–2 (0=no swirling,
1=intermediate swirling, and 2=patent swirling) based on previous
work [25]. Residual leukocytes were counted by flow cytometry (FC)
using Leukocount™ (FACScalibur, Becton Dickinson). Glucose, lactate
and lactate dehydrogenase (LDH) determination were performed on the
Olympus AU 400 Chemistry Analyser. For CD62 P and Annexin V
marker analysis, samples were diluted to 1×106 PLTs/mL and
incubated with phycoerythrin (PE)-conjugated CD62 monoclonal anti-
bodies and fluorescein isothiocyanate (FITC)-conjugated Annexin V
(Becton Dickinson, Immunocytometry Systems, San Jose, CA, USA)
according to the manufacturer protocol before analysis by FC.
Samples harvested in 2008, 2010, and 2012 were centrifuged twice
and frozen at −80 °C before duplicate samples were evaluated for cy-
tokine concentration using ELISA kits (R&D Systems, Minneapolis, MN,
USA) for sCD62 P, sCD40 L following the manufacturer's instructions.
2.5. Statistical analysis
For each assay, longitudinal data captured on days 2, 5, 7, and 9
were analyzed using a generalized estimating equation (GEE). In ad-
dition to the continuous effect of time, a (categorical) treatment group
and a time-by-treatment interaction term were also included as cov-
ariates into the modelling process. Subsequent inference on the cov-
ariate estimates were carried out in order to draw conclusions on the
storage and treatment effect. All models were fit in SAS version 9.4
using the Genmod procedure. In addition, an analysis was performed to
draw conclusions on the storage effect in each treatment arm com-
paring values at day 5, 7, and 9 to values at day 2 of storage using
GraphPad Prism (GraphPad Software, Inc.); The Friedman test followed
by the Dunn’s multiple comparison test or the one-way ANOVA fol-
lowed by the Dunnett’s multiple comparison test, or the Kruskal-Wallis
test followed by the Dunn’s multiple comparison test were used de-
pending on data structure and availability at each time-point.
3. Results
During the 8-year period between April 2008 and April 2016, a total
of 116,214 PI-PCs (BC-PCs and Apheresis-PC) were produced. The last
five-year PC supply production is detailed in Fig. 2, where the mean
increase in the production of PC (from 2011 to 2015) was 2.3%, while
over the same period the supply of red blood cell concentrates dropped
by 4.4%, suggesting that no excessive bleeding occurred while using PI-
PCs. The expiry rate in our center is less than 0.5%.
3.1. Routine QC data demonstrated that PC quality is maintained after
INTERCEPT treatment
Table 2 shows the routine QC results for the period 2013-2015. All
QC parameters were obtained on PCs 14–18 hours post-inactivation and
included platelet content, swirling, residual leucocyte count, and pH
measured at 22 °C at the end of shelf life as required by national and
European guidelines [21,22]. The mean platelet content per unit was
≥3×1011, leukocyte content in all units was< 1×106 leukocytes per
unit, and pH measured at expiration at 22◦C was ≥7.13. Upon visual
inspection, the swirling effect was evident and maintained throughout
storage. None of the PCs tested positive for bacterial contamination. In
our experience, the mean volume and platelet loss after implementing
the INTERCEPT treatment were 7.5% and 8.5%, respectively [26].
3.2. PI-PCs met quality standards for transfusion suitability over time of
storage
Three independent studies were conducted to assess in vitro platelet
metabolism and activation markers in i)- C-PCs in PAS-IIIM in 2010 and
ii)- PI-PCs in PAS-IIIM in 2012 and 2015, to evaluate the effect of PI
treatment on platelet metabolism and activation while production
methods changed replacing PAS-III with PAS-IIIM.
In C-PCs in PAS-IIIM, the mean platelet volume increased slightly
from 8.8 to 9.2 fL (p=0.0048) as a function of storage time. The levels
of lactate dehydrogenase (LDH) increased from 72.4 on day 2 to 92.6
U/L on day 9 (p < 0.0001). Glucose concentration was significantly
impacted and decreased from 5.5 to 1.9 mmol/L from day 2 through 9
(p < 0.0001) while lactate concentration increased significantly from
Fig. 2. Supply of PI-PCs over a 5 year period. Numbers of PI treated BC-PCs and
A-PCs produced at our blood center are shown for the period from 2011
through 2015.
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4.9 on day 2 to 13.3mmol/L on day 9 of storage (p < 0.0001) (Fig. 3).
Platelet count and pH on the other hand did not change significantly
over time of storage (Fig. 3). Platelet activation markers all significantly
increased (p < 0.0001) as a function of storage time in C-PCs in PAS-
IIIM including Annexin V, CD62 after day 7, and sCD40 L sP-selectin
after day 5 of storage (Fig. 4).
When PI-PCs in PAS-IIIM were compared to C-PCs in PAS-IIIM, there
was no difference in platelet quality parameters such as mean platelet
volume (p= 0.18), pH (p=0.95), LDH level (p= 0.12) or lactate
concentration (p=0.86). PI treatment had a slight impact on platelet
count decreasing over time (p= 0.0015) resulting on day 7 in a∼3.5%
platelet loss (compared to< 1% platelet loss in control BC-PCs), though
all units met the requirements in term of platelet content per final unit
of ≥2.5× 1011. While PI-PCs in PAS-IIIM showed a slight increase in
glucose consumption over time of storage compared to C-PCs
(p=0.0002) (Fig. 3), both PI-PCs and C-PCs had sufficient glucose
through day 9 of storage. In PI-PCs, the increase in Annexin V
(p=0.025) and CD62 (p=0.026) expression was slightly higher over
time of storage compared to C-PCs resuspended in the same AS (Fig. 4).
3.3. PAS-IIIM improves platelet storage conditions after PI treatment
Table 3 shows the evolution of platelet metabolism and activation
parameters in PI-PCs resuspended in PAS-III versus PAS-IIIM over time
of storage until day 9.
The pH values decreased as a function of time in all PCs (Fig. 3). The
pH values were not significantly different between PI-PCs and C-PCs
resuspended in PAS-IIIM (p= 0.95). The pH decreased more in PI-PCs
in PAS-III than in PAS-IIIM (p < 0.0001). However in all cases pH
values were maintained above 6.8 at day 7 and 9, and therefore both PI-
PCs in PAS-III or PAS-IIIM met quality standards with pH well above the
6.4 limit [22].
PI-PCs in PAS-III seemed to have higher mean platelet volume
(p < 0.0001) and reduced platelet count (resulting in a 4% platelet
loss by day 7 of storage) (p=0.041). Glucose consumption
(p < 0.0001) and lactate production were both accelerated
(p < 0.0001) over time of storage in PI-PCs in PAS-III compared to
those in PAS-IIIM (Table 3 and Fig. 3), suggesting an accelerated pla-
telet metabolism when PCs were manufactured in PAS-III compared to
PAS-IIIM. By day 7 of storage, while C-PCs and PI-PCs resuspended in
PAS-IIIM had detectable glucose, the PI-PCs in PAS-III had exhausted all
the glucose in the bag. PI-PCs in PAS-III also had higher levels of pla-
telet activation markers such as Annexin V (p= 0.039), CD62
(p=0.0006), and sP-selectin (p=0.0002) expression over time of
storage (Fig. 4), suggesting a better control of platelet activation with
PAS-IIIM. A larger increase in the percentage of CD62-positive platelets
or secreted cytokines was observed for PI-PCs in PAS-III from day 2 to 5
of storage followed by a more moderate increase from day 5 to 9 of
storage, suggesting a stronger platelet activation during the first 5 days
of storage.
4. Discussion
The purpose of this study was to validate the suitability for trans-
fusion of PCs produced using different manufacturing methods. Platelet
quality parameters, metabolism and activation markers were compared
in 2008, and from 2012 to 2015 for PAS-III and PAS-IIIM, respectively.
The results corroborate good platelet quality, and acceptable pH levels
until day 7. Platelets stored in PAS-IIIM maintained platelet number
and glucose levels with low activation throughout storage, as pre-
viously described [8]. Contrary to some of the findings reported in
other publications, there was no significant difference between LDH
levels in PI-PCs in PAS-IIIM compared to PI-PCs in PAS-III. The CD62 P
protein is found in the alpha granules of platelets, and it is expressed on
the platelet surface when they are activated. CD62 expression increased
over time of storage, however values were lower for PCs in PAS-IIIM
than in PAS-III, as previously reported [12]. Although the expression of
CD62 P remained low throughout the storage period in PAS-IIIM PCs,
its clinical significance is not known; in vitro activation of stored pla-
telets did not correlate with in vivo survival and with platelet hemo-
static function after transfusion [27]. Most studies evaluate platelet
quality based on in vitro parameters, while only a limited number of
studies are able to assess the impact in vivo [12]. We observed a small
percentage of Annexin V-positive platelets increasing over time of sto-
rage though the increase in phosphatidylserine exposure remained re-
latively low, less than 10% in all units. This is consistent with previous
reports [28]. The level of adhesion molecule expression and cytokine
secretion were within expected ranges [29,30]. Soluble CD40 L
(sCD40 L) is a powerful immunomodulator that accumulates in the
platelets during storage [31], acts as an inflammatory mediator, and
has been suggested but not proven to be associated with transfusion
adverse reactions [32]. Platelets are the main source of sCD40 L and we
observed a gradual increase during storage but, as previously reported
by others [33], PI treatment did not significantly increase the accu-
mulation of sCD40 L in PI-PCs versus C-PCs.
In this study, in addition to the monthly quality controls, more
comprehensive in vitro studies provided us with additional information
on the quality of the produced PCs. PI treatment resulted only in
minimal additional changes to the ones in C-PCs. A lower platelet count
and a decreased glucose concentration were accompanied by a slightly
increased platelet activation toward the end of the platelet shelf life.
Our region's records of haemovigilance (HV) show that transfusion-
related AE, related to PI-PCs are mild with a mean incidence over the
last 4 years of 0.14%, very similar to the ones observed in the past for C-
PCs. Of note all PCs are manufactured in our center using AS since the
year 2000. In 2013, a case of TRALI was reported, in relation to anti-
bodies to HLA class II antigens in donor to antigens present in the re-
cipient [34]. No cases of PC transfusion-related sepsis, or post-trans-
fusion GVHD were reported during this period. HV multicenter studies
provide information about the safety and efficacy of the treated com-
ponent in a large population [35]. We have participated in the HV study
analysis of 19,175 transfusions of PCs treated with amotosalen-UVA,
Table 2







Volume (mL) 331.2 ± 23.4 338.2 ± 19.8 340.5 ± 13.2
Platelet (PLT) count (x1011/unit) 3.38 ± 0.41 3.42 ± 0.41 3.40 ± 0.42
% of units with ≥ 3×1011 PLTs 87 86.4 87
“Swirling “score 2 2 2
Residual leukocytes < 1×106/unit < 1×106/unit < 1×106/unit
pH (22 °C)a 7.13 ± 0.09 7.18 ± 0.09 7.16 ± 0.10
Tested for bacterial culturea Negativeb Negativeb Negativeb
a At expiration (Day 7).
b Aerobic and anaerobic bottles inoculated with 10mL samples.
A. Castrillo Fernández et al. Transfusion and Apheresis Science 58 (2019) 87–93
90
Fig. 3. Evolution of platelet quality parameters during storage depending on PC manufacturing method. Mean platelet volume, platelet count, pH at 22 °C, LDH,
glucose and lactate concentrations at day 2, 5, 7, 9 of storage are shown for C-PCs (dotted black lines) and PI-PCs resuspended in PAS-IIIM (solid grey lines) or PAS-III
(solid black lines). The graphs show mean ± SEM. P-values by ANOVA < 0.05 are represented by *,< 0.01 by **,< 0.001 by ***,< 0.0001 by **** indicating
significant changes compared to day 2 time-point. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this
article).
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Fig. 4. Platelet activation markers and cytokine levels during storage for different PC manufacturing methods. Frequencies of Annexin V-positive, CD62-positive, sP-
selectin-positive platelets and levels of sCD40 L are shown for C-PCs (dotted black lines), and PI-PCs in PAS-IIIM (solid grey lines) or PAS-III (solid black lines) at day
2, 5, 7, and 9 of storage as available. The graphs show mean ± SEM. P-values by ANOVA < 0.05 are represented by *,< 0.01 by **,< 0.001 by ***,< 0.0001 by
**** indicating significant changes compared to day 2 time-point. (For interpretation of the references to colour in this figure legend, the reader is referred to the web
version of this article).
Table 3
Mean levels for metabolic and activation parameters shown for pathogen inactivated (PI)-PCs depending on the additive solution used.
Day of storage 2 5 7 9 p-value¥
pH A 7.07 ± 0.02 7.03 ± 0.03 6.96 ± 0.04 6.86 ± 0.05
(22 °C) B 7.16 ± 0.07 7.24 ± 0.09 7.25 ± 0.1 7.10 ± 0.12 <0.0001
Glucose A 6.7 ± 0.3 3.8 ± 0.4 1.7 ± 0.5 0.03 ± 0.04
(mmol/L) B 6.3 ± 0.4 4.7 ± 0.6 3.3 ± 0.6 1.64 ± 0.7 <0.0001
Lactate A 5.4 ± 0.4 10.7 ± 0.7 14.4 ± 0.7 17.5 ± 0.7
(mmol/L) B 5.5 ± 0.5 8.3 ± 1.1 11.0 ± 1.04 14.2 ± 1.84 <0.0001
CD62p (%)a A 20.7 ± 3.3 40.6 ± 7.3 44.9 ± 9.2 46.4 ± 6.4
B 9.3 ± 6 17.2 ± 1.9 19.7 ± 5.9 25 ± 10 <0.0006
sP-selectin A 66.3 ± 9.5 115.7 ± 13.9 137.1 ± 20 NT
(ng/mL) B 35.5 ± 8.5 51.8 ± 12 57.7 ± 15.1 77.5 ± 23.2 0.0002
LDH A 74.1 ± 7.2 96.1 ± 13.6 105.1 ± 12.1 112.5 ± 13.0
(U/L) B 98.4 ± 17.6 107.5 ± 17.3 119.4 ± 16.4 129.6 ± 22.9 0.0753
Annexin Va A 2.1 ± 0.7 5.0 ± 3.2 7.4 ± 3.5 10.7 ± 2.2
(%) B 3.0 ± 2.0 4.7 ± 1.8 6.0 ± 2.8. 7.3 ± 3.3 0.0389
A=PI-PCs in PAS-III in 2008 (n= 12).
B= PI-PCs in PAS-IIIM in 2012 and 2015 (n= 24).
NT=not-tested.
a By flow cytometry.
¥ p-value by GEE comparing A and B over time of storage.
A. Castrillo Fernández et al. Transfusion and Apheresis Science 58 (2019) 87–93
92
where a low rate of AE and a safety profile similar to the one for C-PCs
were reported [36].
5. Conclusions
Our QC program allowed for the evaluation of PI-PCs quality over a
8 year-period while PI-PCs were manufactured in PAS-III or PAS-IIIM.
Overall the results demonstrate that all PI-PCs met good quality criteria
with platelet quality parameters and metabolism and activation mar-
kers maintained throughout platelet storage. PI-PCs prepared in PAS-
IIIM appeared to have better retention of in vitro characteristics com-
pared to PAS-III though all demonstrated functionality and clinical ef-
fectiveness. This study highlights the fact that the PI technology using
amotosalen and UVA can be implemented to improve blood safety
while maintaining platelet quality and efficacy.
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